# Insulet Corp: Form 10-Q for the period ended Jun 30, 2021

- Company: [Insulet Corp](/companies/podd.md) (CIK 1145197)
- Form: 10-Q
- Filed: 2021-08-06
- Accepted by EDGAR: Aug 5, 2021, 18:04 ET
- Period: 2021-06-30
- Accession: 0001145197-21-000030
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1145197/000114519721000030/podd-20210630.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1145197/000114519721000030/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-04-01 to 2021-06-30 | $263.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2021-01-01 to 2021-06-30 | $515.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2021-04-01 to 2021-06-30 | $80.5m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2021-01-01 to 2021-06-30 | $165.3m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2021-04-01 to 2021-06-30 | $182.7m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2021-01-01 to 2021-06-30 | $350.2m | us-gaap:GrossProfit |
| Research and development | 3 months, 2021-04-01 to 2021-06-30 | $40.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2021-01-01 to 2021-06-30 | $80.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2021-04-01 to 2021-06-30 | $26.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2021-01-01 to 2021-06-30 | $42.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2021-04-01 to 2021-06-30 | $16.6m | us-gaap:InterestExpense |
| Interest expense | 6 months, 2021-01-01 to 2021-06-30 | $30.2m | us-gaap:InterestExpense |
| Income tax | 3 months, 2021-04-01 to 2021-06-30 | −$3.4m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2021-01-01 to 2021-06-30 | −$3.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2021-04-01 to 2021-06-30 | −$25.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2021-01-01 to 2021-06-30 | −$25.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2021-04-01 to 2021-06-30 | −$0.37 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2021-01-01 to 2021-06-30 | −$0.38 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2021-04-01 to 2021-06-30 | −$0.37 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2021-01-01 to 2021-06-30 | −$0.38 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2021-04-01 to 2021-06-30 | 66,696,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2021-01-01 to 2021-06-30 | 66,406,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2021-01-01 to 2021-06-30 | −$16.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2021-01-01 to 2021-06-30 | $52.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2021-06-30 | $854.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-06-30 | $1.25bn | us-gaap:AssetsCurrent |
| Total assets | at 2021-06-30 | $1.92bn | us-gaap:Assets |
| Current liabilities | at 2021-06-30 | $213.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-06-30 | $1.46bn | us-gaap:Liabilities |
| Long-term debt | at 2021-06-30 | $1.24bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2021-06-30 | $20.9m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2021-06-30 | $459.1m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 35,808 characters.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the accompanying notes included in this quarterly report. The following discussion may contain forward-looking statements that reflect our plans, estimates and beliefs, which are subject to risks, uncertainties and assumptions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to these differences include those discussed under the headings “Risk Factors” and “Forward-Looking Statements” in both our annual report on Form 10-K for the year ended December 31, 2020 and in this quarterly report.

### Overview

We are primarily engaged in the development, manufacture and sale of our proprietary Omnipod® System (“Omnipod”), a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a small, lightweight, self-adhesive disposable tubeless Omnipod device (“Pod”) that is worn on the body for up to three days at a time; and its wireless companion, the handheld Personal Diabetes Manager. The Omnipod System, which features discreet and easy-to-use devices communicates wirelessly, provides for virtually pain-free automated cannula insertion and eliminates the need for traditional multiple daily injection therapy, using syringes or insulin pens, or the use of traditional pump and tubing.

In addition to the diabetes market space, we have partnered with pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas. Most of our drug delivery revenue currently consists of sales of pods to Amgen for use in the Neulasta® Onpro® kit, a delivery system for Amgen’s white blood cell booster to help reduce the risk of infection after intense chemotherapy.

Our mission is to improve the lives of people with diabetes. To assist in achieving this mission, we are focused on the following key strategic imperatives:

- expanding access and awareness;
- delivering consumer-focused innovation;
- growing our global addressable market; and
- driving operational excellence.

Our long-term financial objective is to sustain profitable growth. To achieve this goal, we expect our efforts in 2021 to focus primarily on our planned launch of the Omnipod® 5 Automated Insulin Delivery System (“Omnipod 5”), which is currently under review with the U.S. Food and Drug Administration (“FDA”). This review is taking longer than we had anticipated. We now expect to receive FDA clearance and launch our limited commercial release in the second half of the year, most likely late in the fourth quarter. This shift in timing is not expected to have a material impact on 2021 revenue.

In addition, we continue our efforts to expand the Omnipod 5 indication to preschoolers ages two to six, however the timing of our FDA submission is contingent upon the timing of Omnipod 5 clearance. We are now planning for this expanded indication in 2022. In addition, we completed enrollment in our Type 2 feasibility study and plan to conduct additional studies with the goal to further expand Omnipod 5’s indication to Type 2 users.

In order to support our continued growth and the planned launch of Omnipod 5, we continue to focus on adding capacity to our U.S. manufacturing plant. During the quarter, we began producing salable product on our third highly automated manufacturing line.

In 2021, we launched Omnipod DASH® Insulin Management System (“Omnipod DASH”), our next generation digital mobile Omnipod platform, in Canada. We are also continuing to expand internationally in a targeted and strategic manner. During the first quarter of 2021, we increased our global footprint by expanding into Turkey and we also expect to enter Australia this year. Further, we are working on our strategy to enter additional markets in new regions.

Finally, we plan to continue our product development efforts and expand awareness of and access to our products. Achieving the above strategic imperatives is expected to require additional investments in certain initiatives and personnel, as well as enhancements to our supply chain operation capacity, efficiency and effectiveness.

### Results of Operations

### Revenue

*(dollars in millions)*

|  | Three Months Ended June 30, 2021 | 2020 | Percent Change | Currency Impact | Constant Currency (1) |
| --- | ---: | ---: | ---: | ---: | ---: |
| U.S. Omnipod | $150.5 | $128.8 | 16.8% | —% | 16.8% |
| International Omnipod | 91.6 | 73.2 | 25.1% | 11.7% | 13.4% |
| **Total Omnipod** | 242.1 | 202.0 | 19.9% | 4.3% | 15.6% |
| Drug Delivery | 21.1 | 24.3 | (13.2)% | —% | (13.2)% |
| **Total revenue** | $263.2 | $226.3 | 16.3% | 3.8% | 12.5% |

*(dollars in millions)*

|  | Six Months Ended June 30, 2021 | 2020 | Percent Change | Currency Impact | Constant Currency (1) |
| --- | ---: | ---: | ---: | ---: | ---: |
| U.S. Omnipod | $293.8 | $245.4 | 19.7% | —% | 19.7% |
| International Omnipod | 181.5 | 146.3 | 24.1% | 10.7% | 13.4% |
| **Total Omnipod** | 475.3 | 391.7 | 21.3% | 4.0% | 17.3% |
| Drug Delivery | 40.2 | 32.6 | 23.3% | —% | 23.3% |
| **Total revenue** | $515.5 | $424.3 | 21.5% | 3.7% | 17.8% |

(1) Constant currency revenue growth is a non-GAAP financial measure which should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with GAAP. See “Management’s Use of Non-GAAP Measures.”

Total revenue for the three months ended June 30, 2021 increased $36.9 million, or 16.3%, to $263.2 million, compared with $226.3 million for the three months ended June 30, 2020. Constant currency revenue growth of 12.5% was primarily driven by higher volume and, to a lesser extent, favorable sales channel mix.

Total revenue for the six months ended June 30, 2021 increased $91.2 million, or 21.5%, to $515.5 million, compared with $424.3 million for the six months ended June 30, 2020. Constant currency revenue growth of 17.8% was primarily driven by higher volume and, to a lesser extent, favorable sales channel mix.

#### U.S. Omnipod

U.S. Omnipod revenue for the three months ended June 30, 2021 increased $21.7 million, or 16.8%, to $150.5 million, compared with $128.8 million for the three months ended June 30, 2020. This increase was primarily due to higher volumes driven by growing our customer base, and to a lesser extent, an increase due to growth through the pharmacy channel, where Pods have a higher average selling price due in part to the fact that we offer the PDM for no charge. This increase was partially offset by a decrease in days-on-hand inventory at distributors since COVID-19 supply chain urgency has normalized.

U.S. Omnipod revenue for the six months ended June 30, 2021 increased $48.4 million, or 19.7%, to $293.8 million, compared with $245.4 million for the six months ended June 30, 2020. This increase was primarily due to higher volumes driven by growing our customer base, and to a lesser extent, an increase due to growth through the pharmacy channel, where Pods have a higher average selling price due in part to the fact that we offer the PDM for no charge. For full year 2021, we expect strong U.S. Omnipod revenue growth driven by volume growth of Omnipod DASH, primarily in the pharmacy channel, benefits of our efforts to drive expanded access and awareness, and further growth in our Omnipod customer base.

#### International Omnipod

International Omnipod revenue for the three months ended June 30, 2021 increased $18.4 million, or 25.1%, to $91.6 million, compared with $73.2 million for the three months ended June 30, 2020. Excluding the 11.7% favorable impact of currency exchange, the remaining 13.4% increase in revenue was primarily driven by higher volumes as we continue to expand awareness and access to the Omnipod.

International Omnipod revenue for the six months ended June 30, 2021 increased $35.2 million, or 24.1%, to $181.5 million, compared with $146.3 million for the six months ended June 30, 2020. Excluding the 10.7% favorable impact of currency exchange, the remaining 13.4% increase in revenue was primarily driven by higher volumes as we continue to expand awareness and access to the Omnipod, partially offset by a decrease in days-on-hand inventory at distributors since COVID-19 supply chain urgency has normalized. For full year 2021, we expect higher International Omnipod revenue due to continued volume growth and market penetration aided by the full launch of Omnipod DASH throughout our international markets. We expect this revenue growth to be partially offset by the lagging impact of lower new customer starts in 2020 and the first half of 2021 stemming from COVID-19 and related challenges.

#### Drug Delivery

Drug Delivery revenue for the three months ended June 30, 2021 decreased $3.2 million, or 13.2%, to $21.1 million, compared with $24.3 million for the three months ended June 30, 2020, due to elevated volume in the prior year due to the COVID-19 pandemic.

Drug Delivery revenue for the six months ended June 30, 2021 increased $7.6 million, or 23.3%, to $40.2 million, compared with $32.6 million for the six months ended June 30, 2020, due to increased demand for Amgen’s Neulasta® Onpro® kit which includes our pods. For full year 2021, we expect drug delivery revenue to decline or grow slightly dependent upon forecasted demand.

### Operating Expenses

*(dollars in millions)*

|  | Three Months Ended June 30, 2021 Amount | Percent of Revenue | 2020 Amount | Percent of Revenue |
| --- | ---: | ---: | ---: | ---: |
| Cost of revenue | $80.5 | 30.6% | $83.8 | 37.0% |
| Research and development expenses | $40.1 | 15.2% | $34.2 | 15.1% |
| Selling, general and administrative expenses | $116.3 | 44.2% | $80.8 | 35.7% |

*(dollars in millions)*

|  | Six Months Ended June 30, 2021 Amount | Percent of Revenue | 2020 Amount | Percent of Revenue |
| --- | ---: | ---: | ---: | ---: |
| Cost of revenue | $165.3 | 32.1% | $154.9 | 36.5% |
| Research and development expenses | $80.8 | 15.7% | $69.7 | 16.4% |
| Selling, general and administrative expenses | $226.8 | 44.0% | $164.7 | 38.8% |

#### Cost of Revenue

Cost of revenue for the three months ended June 30, 2021 decreased $3.3 million, or 3.9%, to $80.5 million, compared with $83.8 million for the three months ended June 30, 2020. Gross margin was 69.4% for the three months ended June 30, 2021, compared with 63.0% for the three months ended June 30, 2020. The 640 basis point increase in gross margin was primarily driven by improved manufacturing and supply chain efficiencies, 130 basis points of favorable foreign currency exchange, a 120 basis point decrease in COVID-19 related costs, and a higher average selling price due to growth in the pharmacy channel. These increases were partially offset by expected higher production costs as we continue to scale U.S. manufacturing.

Cost of revenue for the six months ended June 30, 2021 increased $10.4 million, or 6.7%, to 165.3, compared with $154.9 million for the six months ended June 30, 2020. Gross margin was 67.9% for the six months ended June 30, 2021, compared with 63.5% for the six months ended June 30, 2020. The 440 basis point increase in gross margin was primarily driven by improved manufacturing and supply chain efficiencies, higher average selling price due to growth in the pharmacy channel, 120 basis points of favorable foreign currency exchange, and a 110 basis point decrease in COVID-19 related costs. These increases were partially offset by expected higher production costs as we continue to scale U.S. manufacturing. For full year 2021, we expect gross margin to be in the range of 68% to 69%, which reflects expected revenue growth both in the U.S. and internationally, including in the pharmacy channel, and the benefits of continued improvements in manufacturing and supply chain operations. In addition, we expect to benefit from lower COVID-19 related costs.

#### Research and Development Expenses

Research and development expenses for the three months ended June 30, 2021 increased $5.9 million, or 17.3%, to $40.1 million, compared with $34.2 million for the three months ended June 30, 2020. This increase was primarily due to year-over-year headcount additions to support our continued investment in development of Omnipod products.

Research and development expenses for the six months ended June 30, 2021 increased $11.1 million, or 15.9%, to $80.8 million, compared with $69.7 million for the six months ended June 30, 2020. This increase was primarily due to year-over-year headcount additions to support our continued investment in development of Omnipod products. We expect research and development spend for the full year 2021 to increase compared with 2020 as we continue to invest in advancing our innovation and clinical pipeline.

#### Selling, General and Administrative Expenses

Selling general and administrative expenses for the three months ended June 30, 2021 increased $35.5 million, or 43.9%, to $116.3 million, compared with $80.8 million for the three months ended June 30, 2020. This increase was primarily attributable to year-over-year headcount additions, mainly to support international expansion, information technology, sales, and customer service personnel, an increase in direct to consumer advertising spend, as well as a shift in resources and certain costs from our Omnipod 5 clinical efforts to our commercial strategy as we mature as a company.

Selling general and administrative expenses for the six months ended June 30, 2021 increased $62.1 million, or 37.7%, to $226.8 million, compared with $164.7 million for the six months ended June 30, 2020. This increase was primarily attributable to year-over-year headcount additions, mainly to support international expansion, information technology, sales, and customer service personnel, an increase in direct to consumer advertising spend, a shift in resources and certain costs from our Omnipod 5 clinical efforts to our commercial strategy as we mature as a company, as well as commercial costs related to international expansion. We expect selling, general and administrative expenses to increase in 2021 compared with 2020 due to expansion of our sales force, direct-to-consumer advertising, investments to expand market acceptance and access for our products, and investments in our operating structure to facilitate operational efficiencies and continued growth.

### Non-Operating Items

#### Interest Expense, Net

Net interest expense increased $5.3 million to $16.4 million for the three months ended June 30, 2021, compared with $11.1 million for the three months ended June 30, 2020. This increase was driven by $4.6 million of cash interest expense associated with the $500 million senior secured term loan B (the “Term Loan”) entered into in May 2021, and the mortgage and equipment financings that occurred in the fourth quarter of 2020 and a $0.5 million decrease in interest income due to lower market rates and a shift in a portion of our investment portfolio to more liquid investments.

Net interest expense increased $8.6 million to $29.8 million for the six months ended June 30, 2021, compared with $21.2 million for the six months ended June 30, 2020. This increase was driven by $6.2 million of cash interest expense associated with the Term Loan entered into in May 2021, and the mortgage and equipment financings that occurred in the fourth quarter of 2020 and a $1.8 million decrease in interest income due to lower market rates and a shift in a portion of our investment portfolio to more liquid investments.

#### Loss on Extinguishment of Debt

During the three and six months ended June 30, 2021, we incurred a $40.1 million loss on extinguishment of debt related to the repurchase of a portion of our 1.375% Convertible Senior Notes due November 2024 (“1.375% Notes”). Refer to Note 8 to the consolidated financial statements for additional information.

#### Other Income (Expense), Net

During the three months ended June 30, 2021, we had other income, net of $1.8 million, compared with $1.0 million for the three months ended June 30, 2020. The $0.8 million increase in other income was primarily driven by unrealized foreign currency gains due to the change in exchange rates.

During the six months ended June 30, 2021, we had other expense of $0.8 million, compared with income of $1.0 million for the six months ended June 30, 2020. The $1.8 million decrease in other income was primarily driven by unrealized foreign currency losses due to the change in exchange rates.

#### Income Tax Expense, Net

Income tax benefit was $3.4 million for the three months ended June 30, 2021, compared with an income tax expense of $3.0 million for the three months ended June 30, 2020, resulting in effective tax rates of 12.1% and 17.2% for the three months ended June 30, 2021 and 2020, respectively. The decrease in the effective tax rate was primarily driven by the jurisdictional distribution of profits and losses. In the United States, we have net operating loss carryforwards that reduce taxable profits and a full valuation allowance against net deferred tax assets.

Income tax benefit was $3.1 million for the six months ended June 30, 2021, compared with an income tax expense of $2.5 million for the six months ended June 30, 2020, resulting in effective tax rates of 11.2% and 17.0% for the six months ended June 30, 2021 and 2020, respectively. The decrease in the effective tax rate was primarily driven by the jurisdictional distribution of profits and losses. In the United States, we have net operating loss carryforwards that reduce taxable profits and a full valuation allowance against net deferred tax assets. Additionally, we have not recorded tax benefits for current year losses in the United Kingdom due to valuation allowance requirements following a transfer of intellectual property that occurred during the three months ended March 31, 2021.

### Adjusted EBITDA

The table below presents reconciliations of Adjusted EBITDA, a non-GAAP financial measure, to net (loss) income, the most directly comparable financial measure prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”):

*(in millions)*

|  | Three Months Ended June 30, 2021 | 2020 | Six Months Ended June 30, 2021 | 2020 |
| --- | ---: | ---: | ---: | ---: |
| **Net (loss) income** | $(25.0) | $14.4 | $(25.0) | $12.3 |
| Interest expense, net | 16.4 | 11.1 | 29.8 | 21.2 |
| Income tax (benefit) expense | (3.4) | 3.0 | (3.1) | 2.5 |
| Depreciation and amortization | 15.2 | 9.9 | 28.0 | 18.8 |
| Stock-based compensation expense | 9.0 | 5.8 | 17.6 | 13.7 |
| Loss on extinguishment of debt | 40.1 | — | 40.1 | — |
| **Adjusted EBITDA** | $52.3 | $44.2 | $87.4 | $68.5 |

### Non-GAAP Financial Measures

Management uses the following non-GAAP financial measures:

Constant currency revenue growth represents the change in revenue between current and prior year periods using a constant currency, the exchange rate in effect during the applicable prior year period. We present constant currency revenue growth because we believe it provides meaningful information regarding our results on a consistent and comparable basis. Management uses this non-GAAP financial measure, in addition to financial measures in accordance with accounting principles generally accepted in the United States (“GAAP”), to evaluate our operating results. It is also one of the performance metrics that determines management incentive compensation.

Adjusted EBITDA represents net income (loss) plus net interest expense, income tax expense (benefit), depreciation and amortization, stock-based compensation and other significant unusual items, as applicable. We present Adjusted EBITDA because management uses it as a supplemental measure in assessing our operating performance, and we believe that it is helpful to investors, and other interested parties as a measure of our comparative operating performance from period to period. Adjusted EBITDA is a commonly used measure in determining business value and we use it internally to report results.

These non-GAAP financial measures should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with GAAP. In addition, the above definitions may differ from similarly titled measures used by others. Non-GAAP financial measures exclude the effect of items that increase or decrease our reported results of operations; accordingly, we strongly encourage investors to review our consolidated financial statements in their entirety.

### Liquidity and Capital Resources

As of June 30, 2021, we had $854.6 million in cash and cash equivalents and $17.5 million of investments in marketable securities. Additionally, we have a $60 million three year senior secured revolving credit facility (“Revolving Credit Facility”), which expires in 2024. At June 30, 2021, no amount was outstanding under the Revolving Credit Facility. The Revolving Credit Facility contains a covenant to maintain a certain leverage ratio, in addition to other customary covenants, none of which are considered restrictive to our operations. We believe that our current liquidity will be sufficient to meet our projected operating, investing and debt service requirements for at least the next twelve months.

### Debt

To finance our operations and global expansion, we have periodically issued convertible senior notes, which are convertible into our common stock. As of June 30, 2021, the following notes were outstanding:

| Issuance Date | Coupon | Principal Outstanding (in millions) | Due Date | Conversion Rate (1) | Conversion Price per Share of Common Stock |
| --- | ---: | ---: | --- | ---: | ---: |
| November 2017 | 1.375% | $32.1 | November 2024 | 10.7315 | $93.18 |
| September 2019 | 0.375% | 800.0 | September 2026 | 4.4105 | $226.73 |
| **Total** |  | $832.1 |  |  |  |

(1) Per $1,000 face value of notes.

In July 2021, $20.0 million in principal of 1.375% Notes were converted into approximately 215,000 shares, which we expect to result in a loss on extinguishment of debt of approximately $2 million.

During the three months ended June 30, 2021, we obtained a $500 million seven year Term Loan for net proceeds of $489.5 million, which we used to fund the cash portion of repurchase of the 1.375% Notes due November 2024. Additional information regarding our debt is provided in Note 8 to the consolidated financial statements.

### Summary of Cash Flows

*(in millions)*

| Cash (used in) provided by: | Six Months Ended June 30, 2021 | 2020 |
| --- | ---: | ---: |
| Operating activities | $(16.8) | $22.8 |
| Investing activities | (34.1) | 80.6 |
| Financing activities | — | 464.9 |
| Effect of exchange rate changes on cash | (1.7) | (2.9) |
| **Net (decrease) increase in cash, cash equivalents and restricted cash** | $(52.6) | $565.4 |

### Operating Activities

Net cash used in operating activities of $16.8 million for the six months ended June 30, 2021 was primarily attributable to net loss, as adjusted for loss on extinguishment of debt, depreciation and amortization, non-cash interest, and stock-based compensation expense, partially offset by a $104.2 million working capital cash outflow. The working capital outflow was driven by a $45.0 million increase in inventories, a $30.0 million increase in prepaid expenses and other assets and a $19.5 million increase in accounts receivable. The increase in inventories was driven by a planned inventory build to satisfy demand and the addition of our third highly automated manufacturing line. The increase in prepaid expenses and other assets was driven by an increase in cloud computing implementation costs and an increase in unbilled revenue resulting from higher percentage of completion for our Drug Delivery product. Finally, the increase in accounts receivable was primarily due to an increase in International Omnipod revenue and sales in the U.S. pharmacy channel, both of which generally have longer payment terms.

### Investing Activities

Net cash used in investing activities was $34.1 million for the six months ended June 30, 2021, compared with net cash provided by investing activities of $80.6 million for the six months ended June 30, 2020.

*Capital Spending—*Capital expenditures were $52.8 million and $51.7 million for the six months ended June 30, 2021 and 2020, respectively, and primarily related to the purchase of equipment to increase our manufacturing capacity. We expect capital expenditures for 2021 to increase compared with 2020 as we continue to further invest in our global manufacturing operations to support our growth, as well as investments in our strategic initiatives. We expect to fund our capital expenditures using existing cash and investments.

*Purchases and Sales of Investments—*Proceeds from maturities of marketable securities were $22.5 million for the six months ended June 30, 2021, compared with net proceeds from maturities of $132.8 million for the six months ended June 30, 2020. The $110.3 million decrease was driven by the prior year shift in a portion of our investment portfolio to investments classified as cash equivalents.

### Financing Activities

We had no cash provided by financing activities for the six months ended June 30, 2021, compared with $464.9 million for six months ended June 30, 2020.

*Debt Issuance and Repayments—*During the six months ended June 30, 2021, we received net proceeds of $489.5 million from the issuance of the Term Loan and used $460.8 million of cash to partially fund the repurchase of a portion of our 1.375% Notes. Additionally, we spent $6.4 million on principal payments associated with our equipment financings.

*Option Exercises and Payment of Taxes for Restricted Stock Net Settlements—*Total proceeds from option exercises and issuance of employee stock purchase plan shares was $10.0 million and $14.2 million for the six months ended June 30, 2021 and 2020, respectively. The $4.2 million decrease was primarily driven by fewer option exercises by our former chief executive officer. Payments for taxes related to net restricted and performance stock unit settlements were $27.3 million and $26.8 million for the six months ended June 30, 2021 and 2020, respectively.

### Legal Proceedings

The significant estimates and judgments related to establishing litigation reserves are discussed under “Legal Proceedings” in Note 10 to the consolidated financial statements included in this Form 10-Q.

### Off-Balance Sheet Arrangements

As of June 30, 2021, we had various outstanding letters of credit and bank guarantees totaling $2.8 million, none of which is individually significant. We have restricted cash that serves as collateral for these outstanding letters of credit and bank guarantees that are included in cash and cash equivalents on our consolidated balance sheet.

### Critical Accounting Policies and Estimates

The preparation of our consolidated financial statements in conformity with GAAP requires management to use judgment in making estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities.

Our accounting policies for revenue recognition and contingencies are based on, among other things, judgments and assumptions made by management that include inherent risks and uncertainties. There have been no significant changes to the above critical accounting policies or in the underlying accounting assumptions and estimates used in such policies from those disclosed in our annual consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2020.

### Accounting Standards Issued and Not Yet Adopted

In August 2020, the FASB issued ASU 2020-06, *Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity,* which simplifies the accounting for convertible instruments by eliminating certain separation models. Under ASU 2020-06, a convertible debt instrument will generally be reported as a single liability at its amortized cost with no separate accounting for embedded conversion features. Consequently, the interest rate of convertible debt instruments will be closer to the coupon interest rate. In addition, ASU 2020-06 eliminates the treasury stock method to calculate diluted earnings per share for convertible instruments and requires the use of the if-converted method. The guidance is effective for us beginning in the first quarter of 2022. Based on the carrying value of our convertible debt as of June 30, 2021 and subsequent conversion of 1.375% Notes in July 2021, the adoption of this guidance on January 1, 2022 is expected to result in an approximate $215 million decrease in additional paid in capital from the derecognition of the bifurcated equity component, $155 million increase in debt from the derecognition of the discount associated with the bifurcated equity component and $60 million decrease to the opening balance of accumulated deficit, representing the cumulative interest expense recognized related to the amortization of the bifurcated conversion option. We expect to write-off the related deferred tax liabilities with a corresponding adjustment to the valuation allowance, resulting in no net impact to the cumulative adjustment to retained earnings. Adoption of this standard will have no impact on our diluted earnings per share as we calculate earnings per share using the if-converted method.

### FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q contains forward-looking statements. Forward-looking statements relate to future events or our future financial performance. We generally identify forward looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar words. These statements are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, results of operations and financial condition.

The outcomes of the events described in these forward-looking statements are subject to risks, uncertainties and assumptions. These risks and uncertainties include, but are not limited to:

- risks associated with public health crises and pandemics, such as the COVID-19 global pandemic, including the duration of the outbreak, government actions and restrictive measures implemented in response, supply chain disruptions, delays in clinical trials, and other impacts to the business, or on our ability to execute business continuity plans;
- risks associated with our dependence on our principal product platform, the Omnipod System, and our ability to design, develop, manufacture and commercialize future products;
- our ability to reduce production costs and increase customer orders and manufacturing volumes;
- adverse changes in general economic conditions;
- the impact of healthcare reform laws;
- supply problems or price fluctuations with sole source or third-party suppliers on which we are dependent;
- the potential establishment of a competitive bid program for conventional insulin pumps;
- failure to retain key suppliers and/or supplier pricing discounts and achieve satisfactory gross margins;
- international business risks, including regulatory, commercial and logistics risks associated with selling our products in Europe due to the separation of the United Kingdom from the European Union (Brexit);
- our inability to secure and retain adequate coverage or reimbursement from third-party payors for the Omnipod System or future products and potential adverse changes in reimbursement rates or policies relating to the Omnipod System or future products;
- failure to retain key payor partners and their members;
- adverse effects resulting from competition;
- technological change and product innovation adversely affecting our business;
- changes to or termination of our license to incorporate a blood glucose meter into the Omnipod System or our inability to enter into new license or other agreements with respect to the Omnipod System’s current or future features;
- challenges to the future development of our non-insulin drug delivery product line;
- our ability to protect our intellectual property and other proprietary rights;
- conflicts with the intellectual property of third parties, including claims that our current or future products infringe or misappropriate the proprietary rights of others;
- adverse regulatory or legal actions relating to the Omnipod System or future products;
- failure of our contract manufacturers or component suppliers to comply with the FDA’s quality system regulations;
- potential adverse impacts resulting from a recall, or discovery of serious safety issues, of the Omnipod System;
- the potential violation of the U.S. Foreign Corrupt Practices Act or any other federal, state or foreign anti-bribery/anti-corruption laws or laws prohibiting “kickbacks” or protecting the confidentiality of health information or other protected personal information, or any challenge to or investigation into our practices under these laws;
- product liability and other lawsuits that may be brought against us, including stemming from off-label use of our product;
- breaches or failures of our product or information technology systems, including by cyber-attack;
- reduced retention rates of our customer base;
- unfavorable results of clinical studies relating to the Omnipod System or future products, or the products of our competitors;
- future publication of articles or announcement of positions by diabetes associations or other organizations that are unfavorable to the Omnipod System;
- the concentration of our manufacturing operations and storage of our inventory in a limited number of locations;
- our ability to attract and retain personnel;
- our ability to scale our business to support revenue growth;
- fluctuations in quarterly results of operations;
- risks associated with potential future acquisitions or investments in new businesses;
- our ability to generate sufficient cash to service all of our indebtedness or raise additional funds on acceptable terms or at all;
- the expansion of our distribution network;
- the volatility of the trading price of our common stock;
- risks related to future sales of our common stock or the conversion of any of our convertible debt;
- potential limitations on our ability to use our net operating loss carryforwards; and
- anti-takeover provisions in our organizational documents.

The risk factors discussed in “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020 and in this Quarterly Report could cause our results to differ materially from those expressed in forward-looking statements. In addition, there may be other risks and uncertainties that we are unable to predict at this time or that we currently do not expect to have a material adverse effect on our business. Actual results could differ materially from those projected in the forward-looking statements; accordingly, you should not rely upon forward-looking statements as predictions of future events. We expressly disclaim any obligation to update these forward-looking statements other than as required by law.

## Market risk

As filed, 1,049 characters.

#### Interest Rate Risk

Our exposure to changes in interest rates is associated with borrowings under our Revolving Credit Facility and our Term Loan, both of which are variable-rate debt. At June 30, 2021, no amounts were outstanding under our Revolving Credit Facility. In May 2021, we entered into two interest rate swap agreements to effectively convert $480 million of our term loan borrowings from a variable rate to a fixed rate. These interest rate swaps are intended to mitigate the exposure to fluctuations in interest rates and qualify for hedge accounting treatment as cash flow hedges. A 100 basis point increase or decrease in interest rates relative to interest rates as of June 30, 2021 would decrease or increase our annual earnings, respectively, by approximately $0.2 million.

Refer to “Part II. Item 7A. Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report on Form 10-K for the year ended December 31, 2020 for a discussion of our market price sensitive instruments and foreign currency exchange risk.

## Controls and procedures

As filed, 1,274 characters.

### Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures designed to ensure that information required to be disclosed in reports filed under the Securities Exchange Act of 1934 (“the Exchange Act”), as amended, is recorded, processed, summarized and reported within the specified time periods, and that such information is accumulated and communicated to management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of June 30, 2021. Based on the evaluation, our chief executive officer and chief financial officer concluded that, as of that date, our disclosure controls and procedures were effective.

### Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the three months ended June 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 337 characters.

Please refer to the “Risks Factors” section in our Annual Report on Form 10-K for the year ended December 31, 2020 for a discussion of risks to which our business, financial condition, results of operations and cash flows are subject. There have been no material changes to the risk factors disclosed in the aforementioned Annual Report.

Filed Aug 6, 2021.
Source: SEC EDGAR, the filing index for accession 0001145197-21-000030. Last ingested by Listed: Nov 14, 2026, 12:01 ET. No prices; not investment advice.
